Financial Health Assessment: CLINICAL PHARMACIST SOLUTIONS LTD

Financial Health Score: B+

The company demonstrates robust financial vitality with impressive growth trajectory and strong profitability, but exhibits symptoms that require monitoring—specifically around cash flow volatility and debtor concentration. Like a patient with excellent muscle tone but occasional irregular heartbeat, the underlying health is sound, but certain vital signs warrant closer observation.

1. Key Vital Signs

Growth Metrics — Excellent

The company has grown from net assets of £11,426 at incorporation to nearly £1 million in just six years—a remarkable expansion that suggests the business model is delivering real value to the healthcare sector.

Profitability — Strong

• Retained Profit (2026): £963,698 (up from £597,660)
• Profit Added in Year: Approximately £366,038
• Profit Margin Trend: Consistently profitable since 2020, with only a minor dip in 2022

The P&L reserve tells a story of sustained profitability—like a healthy metabolism converting revenue into retained energy efficiently.

Liquidity — Adequate but Variable

The current ratio above 1.5 indicates the company can meet its short-term obligations, but the dramatic cash fluctuation—from £361,120 (2024) to £5,413 (2025) to £448,478 (2026)—is a symptom that requires diagnosis.

Leverage — Healthy

• Long-term Debt: Eliminated entirely in 2026 (was £89,900 in 2025)
• Debt-to-Equity Ratio: Minimal—liabilities are predominantly current trade creditors

The company has paid off its long-term borrowing, leaving it with a clean balance sheet structure. This is analogous to a patient who has successfully completed a rehabilitation programme and is now operating without external support.

2. Symptoms Analysis

Symptom 1: Cash Flow Volatility — Moderate Concern

The cash position has swung dramatically:

This volatility could indicate: - Seasonal timing of NHS or GP surgery payments - Large contract milestones that create lumpy cash inflows - Working capital management challenges during growth phases

The recovery to £448,478 in 2026 is reassuring, but the near-zero position in 2025 suggests the company was operating with dangerously thin cash reserves—like a patient whose blood pressure occasionally dips to concerning levels.

Symptom 2: High Debtor Concentration — Moderate Concern

• Debtors (2026): £1,626,415 (78% of current assets)
• Debtors (2025): £1,200,905

The company has over £1.6 million owed by customers. While this is common in healthcare contracting with NHS-related bodies, it represents significant working capital tied up. If even a small percentage of these debtors proved slow-paying or uncollectable, it could create a cash flow emergency.

Symptom 3: Director's Loan — Observation Required

• Amount Outstanding: £657,803 (down from £660,432)
• Terms: Unsecured, repayable on demand, 3.75% interest
• Purpose: Property purchase by the director

This substantial loan represents funds the company owes to its director. While the slight repayment (£124,000 received, offset by £121,371 advanced) shows some activity, the balance remains significant. This is like a patient with a benign growth—it's not immediately dangerous, but its size and nature warrant regular monitoring.

Symptom 4: Employee Growth — Positive Indicator

• Average Employees: 55 (2026) vs 50 (2025) — 10% increase

Staff growth alongside profitability suggests the company is investing in capacity to meet demand—a healthy sign of organic expansion.

3. Diagnosis

Overall Financial Condition: Healthy with Watch Areas

Clinical Pharmacist Solutions Ltd presents as a vigorously growing business with strong underlying health. The company has:

✅ Strengths: - Consistent and impressive profitability - Strong net asset growth trajectory - No long-term debt - Healthy current ratio - Growing workforce aligned with business expansion - Director confidence evidenced by ongoing investment

⚠️ Watch Areas: - Cash flow volatility that could become critical during lean periods - High debtor concentration creating working capital dependency - Large director's loan that represents a potential call on company resources - Rapid growth that requires careful management to sustain

The 2025 cash position of £5,413 was a near-miss event—like a patient who narrowly avoided a crisis. The recovery in 2026 is encouraging, but the underlying pattern suggests the company may be operating with tighter cash headroom than is prudent.

4. Prognosis

Future Outlook: Positive with Conditions

The company's trajectory is strongly positive. Operating in the healthcare sector with NHS-related services provides relatively stable demand, and the business model of supplying clinical pharmacists to GP surgeries addresses a genuine market need.

However, the prognosis depends on:

1. Cash Management: If the company experiences another cash trough similar to 2025, it may need to rely on director support or external facilities
2. Debtor Collection: Efficient collection of the £1.6M in debtors is essential for maintaining healthy cash flow
3. Growth Sustainability: The company must ensure growth doesn't outpace its working capital capacity

5. Recommendations

Immediate Actions (Within 3 Months)

1. Cash Flow Forecasting: Implement rolling 13-week cash flow forecasts to provide early warning of potential cash shortfalls. This is the financial equivalent of continuous cardiac monitoring—it won't prevent problems, but it ensures you see them coming.

2. Debtor Management: Review the aged debtor schedule and implement structured collection processes. Consider offering early payment discounts to NHS clients or factoring arrangements for larger contracts.

3. Director's Loan Review: Establish a formal repayment schedule for the £657,803 director's loan to provide certainty for both the director and the company's cash flow planning.

Medium-Term Actions (3-12 Months)

4. Cash Reserve Policy: Build and maintain a minimum cash reserve equivalent to 3 months of operating expenses. Based on current liabilities of £1.1M, this suggests a target cash balance of approximately £275,000 minimum.

5. Working Capital Facility: Consider establishing a revolving credit facility or overdraft arrangement to provide a safety net during periods of high debtor balances.

6. Growth Planning: Develop detailed financial projections for the next 2-3 years that model the working capital requirements of continued expansion. Growth requires fuel, and understanding the cash implications of hiring more staff is essential.

Long-Term Strategic Considerations

7. Revenue Diversification: Explore opportunities to diversify the client base beyond GP surgeries to reduce concentration risk.

8. Succession Planning: With a single director and significant PSC involvement, consider governance strengthening and succession planning to protect the business's continuity.